Abstract | BACKGROUND: METHODS: RESULTS:
Paclitaxel showed significant antitumor activity against MCF-7 and MX-1, but only limited activity against the other three xenografts (R-27, Br-10, and T-61), suggesting its substantially different antitumor spectrum from conventional antibreast cancer drugs. The different sensitivity of xenografts to paclitaxel was successfully reproduced in vitro using the MTT assay, when the cutoff concentration of paclitaxel was 20 microg/ml. CONCLUSION: Since no significant differences were observed in the pharmacokinetics of paclitaxel in sensitive and resistant tumor cell lines, the efficacy of this agent seemed to depend on the sensitivity of tumor cells rather than the intratumoral concentration of agent.
|
Authors | T Kubota, S W Matsuzaki, Y Hoshiya, M Watanabe, M Kitajima, F Asanuma, Y Yamada, J I Koh |
Journal | Journal of surgical oncology
(J Surg Oncol)
Vol. 64
Issue 2
Pg. 115-21
(Feb 1997)
ISSN: 0022-4790 [Print] United States |
PMID | 9047247
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents, Phytogenic
- Coloring Agents
- Tetrazolium Salts
- Thiazoles
- Mitomycin
- Doxorubicin
- Cyclophosphamide
- thiazolyl blue
- Paclitaxel
|
Topics |
- Animals
- Antineoplastic Agents, Phytogenic
(pharmacokinetics, pharmacology)
- Breast Neoplasms
(drug therapy, metabolism, pathology)
- Coloring Agents
- Cyclophosphamide
(pharmacology)
- Doxorubicin
(pharmacology)
- Drug Resistance, Neoplasm
- Female
- Humans
- Mice
- Mice, Nude
- Mitomycin
(pharmacology)
- Neoplasm Transplantation
- Paclitaxel
(pharmacokinetics, pharmacology)
- Tetrazolium Salts
- Thiazoles
- Transplantation, Heterologous
- Tumor Cells, Cultured
(drug effects)
|